The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China

Not yet recruitingOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2027

Conditions

MigraineMigraine Prophylaxis

Interventions

DRUG

Rimegepant

Female migraine patients take Rimegepant (75mg QOD) as their regular prophylactic treatment of migraine for 12 weeks

All Listed Sponsors

lead

The First Affiliated Hospital of Soochow University

OTHER

NCT06728345 - The Real-world Study of Rimegepant Treatment in Female Migraine Patients of China | Biotech Hunter | Biotech Hunter